SAFETY DATA SHEET
according to Regulation (EC) No. 1907/2006

Moxifloxacin Solid Formulation

Version 2.2
Revision Date: 09/13/2019
SDS Number: 1732314-00006
Date of last issue: 24.04.2019
Date of first issue: 05.06.2017

SECTION 1: Identification of the substance/mixture and of the company/undertaking

1.1 Product identifier
Trade name: Moxifloxacin Solid Formulation

1.2 Relevant identified uses of the substance or mixture and uses advised against
Use of the Substance/Mixture: Pharmaceutical

1.3 Details of the supplier of the safety data sheet
Company: MSD
Shotton Lane
NE23 3JU Cramlington NU - Great Britain
Telephone: 44 1 670 59 30 00
Telefax: 908-735-1496
E-mail address of person responsible for the SDS: EHSDATASTEWARD@msd.com

1.4 Emergency telephone number
1-908-423-6000

SECTION 2: Hazards identification

2.1 Classification of the substance or mixture
Classification (REGULATION (EC) No 1272/2008)
Acute toxicity, Category 4
H302: Harmful if swallowed.
Eye irritation, Category 2
H319: Causes serious eye irritation.
Reproductive toxicity, Category 2
H361d: Suspected of damaging the unborn child.
Specific target organ toxicity - repeated exposure, Category 2
H373: May cause damage to organs through prolonged or repeated exposure.

2.2 Label elements
Labelling (REGULATION (EC) No 1272/2008)
Hazard pictograms:

Signal word: Warning
Hazard statements:
H302: Harmful if swallowed.
H319: Causes serious eye irritation.
H361d: Suspected of damaging the unborn child.
H373: May cause damage to organs through prolonged or repeated exposure.
Precautionary statements:

**Prevention:**
- P201 Obtain special instructions before use.
- P270 Do not eat, drink or smoke when using this product.
- P280 Wear protective gloves/ protective clothing/ eye protection/ face protection.

**Response:**
- P301 + P312 + P330 IF SWALLOWED: Call a POISON CENTER/doctor if you feel unwell. Rinse mouth.
- P308 + P313 IF exposed or concerned: Get medical advice/ attention.
- P337 + P313 If eye irritation persists: Get medical advice/ attention.

Hazardous components which must be listed on the label:
Moxifloxacin HCL

**2.3 Other hazards**
None known.

**SECTION 3: Composition/information on ingredients**

**3.2 Mixtures**

<table>
<thead>
<tr>
<th>Components</th>
<th>CAS-No.</th>
<th>Classification</th>
<th>Concentration (% w/w)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Moxifloxacin HCL</td>
<td>186826-86-8</td>
<td>Acute Tox.4; H302 Eye Irrit.2; H319 Repr.2; H361d STOT RE2; H373</td>
<td>&gt;= 40 - &lt;= 70</td>
</tr>
</tbody>
</table>

For explanation of abbreviations see section 16.

**SECTION 4: First aid measures**

**4.1 Description of first aid measures**

**General advice**:
In the case of accident or if you feel unwell, seek medical advice immediately. When symptoms persist or in all cases of doubt seek medical advice.

**Protection of first-aiders**:
First Aid responders should pay attention to self-protection, and use the recommended personal protective equipment when the potential for exposure exists (see section 8).

**If inhaled**:
If inhaled, remove to fresh air. Get medical attention.

**In case of skin contact**:
In case of contact, immediately flush skin with soap and plenty...
of water.
Remove contaminated clothing and shoes.
Get medical attention.
Wash clothing before reuse.
Thoroughly clean shoes before reuse.

In case of eye contact :
In case of contact, immediately flush eyes with plenty of water for at least 15 minutes.
If easy to do, remove contact lens, if worn.
Get medical attention.

If swallowed :
If swallowed, DO NOT induce vomiting.
Get medical attention.
Rinse mouth thoroughly with water.
Never give anything by mouth to an unconscious person.

4.2 Most important symptoms and effects, both acute and delayed
Risks :
Harmful if swallowed.
Causes serious eye irritation.
Suspected of damaging the unborn child.
May cause damage to organs through prolonged or repeated exposure.

4.3 Indication of any immediate medical attention and special treatment needed
Treatment :
Treat symptomatically and supportively.

SECTION 5: Firefighting measures

5.1 Extinguishing media
Suitable extinguishing media :
Water spray
Alcohol-resistant foam
Carbon dioxide (CO2)
Dry chemical

Unsuitable extinguishing media :
None known.

5.2 Special hazards arising from the substance or mixture
Specific hazards during firefighting :
Exposure to combustion products may be a hazard to health.

Hazardous combustion products :
Carbon oxides

5.3 Advice for firefighters
Special protective equipment for firefighters :
In the event of fire, wear self-contained breathing apparatus.
Use personal protective equipment.

Specific extinguishing method :
Use extinguishing measures that are appropriate to local cir-
SAFETY DATA SHEET
according to Regulation (EC) No. 1907/2006

Moxifloxacin Solid Formulation

SECTION 6: Accidental release measures

6.1 Personal precautions, protective equipment and emergency procedures

Personal precautions: Use personal protective equipment. Follow safe handling advice and personal protective equipment recommendations.

6.2 Environmental precautions

Environmental precautions: Discharge into the environment must be avoided. Prevent further leakage or spillage if safe to do so. Retain and dispose of contaminated wash water. Local authorities should be advised if significant spillages cannot be contained.

6.3 Methods and material for containment and cleaning up

Methods for cleaning up: Sweep up or vacuum up spillage and collect in suitable container for disposal. Local or national regulations may apply to releases and disposal of this material, as well as those materials and items employed in the cleanup of releases. You will need to determine which regulations are applicable. Sections 13 and 15 of this SDS provide information regarding certain local or national requirements.

6.4 Reference to other sections

See sections: 7, 8, 11, 12 and 13.

SECTION 7: Handling and storage

7.1 Precautions for safe handling

Technical measures: See Engineering measures under EXPOSURE CONTROLS/PERSONAL PROTECTION section.
Local/Total ventilation: Use only with adequate ventilation.
Advice on safe handling: Do not swallow. Do not get in eyes. Avoid prolonged or repeated contact with skin. Handle in accordance with good industrial hygiene and safety practice, based on the results of the workplace exposure assessment. Take care to prevent spills, waste and minimize release to the environment.

Hygiene measures: If exposure to chemical is likely during typical use, provide eye flushing systems and safety showers close to the working place. When using do not eat, drink or smoke. Wash contami-
A detailed list of personal protective equipment is also provided, including:

- **Eye protection:** Wear safety glasses with side shields or goggles.
- **Hand protection:** Chemical-resistant gloves.
- **Skin and body protection:** Work uniform or laboratory coat.
- **Respiratory protection:** Particulates type (P)

In summary, the document emphasizes the importance of proper engineering controls, personal protective equipment, and medical surveillance to ensure the safe handling and use of Moxifloxacin Solid Formulation.
Moxifloxacin Solid Formulation

SECTION 9: Physical and chemical properties

9.1 Information on basic physical and chemical properties

- **Appearance**: solid
- **Colour**: pink
- **Odour**: odourless
- **Odour Threshold**: No data available
- **pH**: No data available
- **Melting point/freezing point**: No data available
- **Initial boiling point and boiling range**: No data available
- **Flash point**: Not applicable
- **Evaporation rate**: No data available
- **Flammability (solid, gas)**: Not classified as a flammability hazard
- **Upper explosion limit / Upper flammability limit**: No data available
- **Lower explosion limit / Lower flammability limit**: No data available
- **Vapour pressure**: No data available
- **Relative vapour density**: No data available
- **Relative density**: No data available
- **Density**: No data available
- **Solubility(ies)**
  - **Water solubility**: No data available
  - **Partition coefficient: n-octanol/water**: No data available
  - **Auto-ignition temperature**: No data available
  - **Decomposition temperature**: No data available
- **Viscosity**
  - **Viscosity, kinematic**: No data available
- **Explosive properties**: Not explosive
- **Oxidizing properties**: The substance or mixture is not classified as oxidizing.

9.2 Other information

- **Flammability (liquids)**: No data available
Moxifloxacin Solid Formulation

Molecular weight : Not applicable
Particle size : No data available

SECTION 10: Stability and reactivity

10.1 Reactivity
Not classified as a reactivity hazard.

10.2 Chemical stability
Stable under normal conditions.

10.3 Possibility of hazardous reactions
Hazardous reactions : Can react with strong oxidizing agents.

10.4 Conditions to avoid
Conditions to avoid : None known.

10.5 Incompatible materials
Materials to avoid : Oxidizing agents

10.6 Hazardous decomposition products
No hazardous decomposition products are known.

SECTION 11: Toxicological information

11.1 Information on toxicological effects
Information on likely routes of exposure :
Skin contact
Ingestion
Eye contact

Acute toxicity
Harmful if swallowed.

Product:
Acute oral toxicity : Acute toxicity estimate: 1.886 mg/kg
Method: Calculation method

Components:
Moxifloxacin HCL:
Acute oral toxicity : LD50 (Rat): 1.320 mg/kg
LD50 (Mouse): > 435 mg/kg
LD50 (Monkey): 1.500 mg/kg

Skin corrosion/irritation
Not classified based on available information.
Components:

Moxifloxacin HCL:
Species: Rabbit
Result: No skin irritation

Serious eye damage/eye irritation
Causes serious eye irritation.

Components:

Moxifloxacin HCL:
Species: Rabbit
Result: Moderate eye irritation

Respiratory or skin sensitisation

Skin sensitisation
Not classified based on available information.

Respiratory sensitisation
Not classified based on available information.

Germ cell mutagenicity
Not classified based on available information.

Components:

Moxifloxacin HCL:
Genotoxicity in vitro:
Test Type: Bacterial reverse mutation assay (AMES)
Result: positive
Test Type: Chromosome aberration test in vitro
Result: negative
Test Type: In vitro mammalian cell gene mutation test
Result: negative
Test Type: In vitro micronucleus test
Result: negative

Genotoxicity in vivo:
Test Type: Mammalian erythrocyte micronucleus test (in vivo cytogenetic assay)
Application Route: Oral
Result: negative

Carcinogenicity
Not classified based on available information.

Reproductive toxicity
Suspected of damaging the unborn child.
Components:
Moxifloxacin HCL:
Effects on fertility: Test Type: Fertility/early embryonic development
Species: Rat
Application Route: Oral
Fertility: LOAEL: 500 mg/kg body weight
Result: Effects on fertility

Effects on foetal development: Test Type: Embryo-foetal development
Species: Monkey
Application Route: Oral
Developmental Toxicity: NOAEL: 10 mg/kg body weight
Result: negative

Test Type: Embryo-foetal development
Species: Rabbit
Application Route: Intravenous injection
Developmental Toxicity: LOAEL: 20 mg/kg body weight
Symptoms: Skeletal malformations

Reproductive toxicity - Assessment: Some evidence of adverse effects on development, based on animal experiments.

STOT - single exposure
Not classified based on available information.

STOT - repeated exposure
May cause damage to organs through prolonged or repeated exposure.

Components:
Moxifloxacin HCL:
Target Organs: Liver
Assessment: May cause damage to organs through prolonged or repeated exposure.

Repeated dose toxicity

Components:
Moxifloxacin HCL:
Species: Rat
LOAEL: 100 mg/kg
Application Route: Oral
Exposure time: 4 Weeks

Species: Rat
NOAEL: 100 mg/kg
Application Route: Oral
Exposure time: 13 Weeks
Target Organs: Liver
Symptoms: Liver disorders
# Moxifloxacin Solid Formulation

<table>
<thead>
<tr>
<th>Species</th>
<th>Rat</th>
</tr>
</thead>
<tbody>
<tr>
<td>NOAEL</td>
<td>20 mg/kg</td>
</tr>
<tr>
<td>Application Route</td>
<td>Oral</td>
</tr>
<tr>
<td>Exposure time</td>
<td>6 Months</td>
</tr>
<tr>
<td>Target Organs</td>
<td>Liver</td>
</tr>
<tr>
<td>Symptoms</td>
<td>Liver disorders</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Species</th>
<th>Monkey</th>
</tr>
</thead>
<tbody>
<tr>
<td>NOAEL</td>
<td>50 mg/kg</td>
</tr>
<tr>
<td>Application Route</td>
<td>Oral</td>
</tr>
<tr>
<td>Exposure time</td>
<td>4 Weeks</td>
</tr>
<tr>
<td>Symptoms</td>
<td>No adverse effects</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Species</th>
<th>Monkey</th>
</tr>
</thead>
<tbody>
<tr>
<td>NOAEL</td>
<td>15 mg/kg</td>
</tr>
<tr>
<td>Application Route</td>
<td>Oral</td>
</tr>
<tr>
<td>Exposure time</td>
<td>13 Weeks</td>
</tr>
<tr>
<td>Target Organs</td>
<td>Gastrointestinal tract</td>
</tr>
<tr>
<td>Symptoms</td>
<td>Vomiting</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Species</th>
<th>Monkey</th>
</tr>
</thead>
<tbody>
<tr>
<td>Application Route</td>
<td>Oral</td>
</tr>
<tr>
<td>Exposure time</td>
<td>26 Weeks</td>
</tr>
<tr>
<td>Target Organs</td>
<td>Liver</td>
</tr>
<tr>
<td>Symptoms</td>
<td>Liver disorders</td>
</tr>
</tbody>
</table>

**Aspiration toxicity**
Not classified based on available information.

**Experience with human exposure**

**Components:**

Moxifloxacin HCL:

| Ingestion  | Symptoms: Nausea, Abdominal pain, Headache, Dizziness, central nervous system effects, joint pain |

# SECTION 12: Ecological information

**12.1 Toxicity**
No data available

**12.2 Persistence and degradability**
No data available

**12.3 Bioaccumulative potential**
No data available

**12.4 Mobility in soil**
No data available

**12.5 Results of PBT and vPvB assessment**
Not relevant
12.6 Other adverse effects
No data available

SECTION 13: Disposal considerations

13.1 Waste treatment methods
Product : Dispose of in accordance with local regulations. According to the European Waste Catalogue, Waste Codes are not product specific, but application specific. Waste codes should be assigned by the user, preferably in discussion with the waste disposal authorities.
Contaminated packaging : Empty containers should be taken to an approved waste handling site for recycling or disposal. If not otherwise specified: Dispose of as unused product.

SECTION 14: Transport information

14.1 UN number
Not regulated as a dangerous good

14.2 UN proper shipping name
Not regulated as a dangerous good

14.3 Transport hazard class(es)
Not regulated as a dangerous good

14.4 Packing group
Not regulated as a dangerous good

14.5 Environmental hazards
Not regulated as a dangerous good

14.6 Special precautions for user
Not applicable

14.7 Transport in bulk according to Annex II of Marpol and the IBC Code
Remarks : Not applicable for product as supplied.

SECTION 15: Regulatory information

15.1 Safety, health and environmental regulations/legislation specific for the substance or mixture
REACH - Restrictions on the manufacture, placing on the market and use of certain dangerous substances, preparations and articles (Annex XVII) : Not applicable
REACH - Candidate List of Substances of Very High Concern for Authorisation (Article 59) : Not applicable
REACH - List of substances subject to authorisation (Annex XIV) : Not applicable
Regulation (EC) No 1005/2009 on substances that deplete the ozone layer : Not applicable
Regulation (EC) No 850/2004 on persistent organic pollutants : Not applicable
Regulation (EC) No 649/2012 of the European Parliament and the Council concerning the export and import of dangerous chemicals
Not applicable

Other regulations:
Take note of Directive 92/85/EEC regarding maternity protection or stricter national regulations, where applicable.
Young people under the age of 18 are not allowed to use or be exposed to the product professionally. Young people above the age of 15 are, however, except from this rule if the product is a necessary part of their education.

The components of this product are reported in the following inventories:
AICS : not determined
DSL : not determined
IECSC : not determined

15.2 Chemical safety assessment
A Chemical Safety Assessment has not been carried out.

SECTION 16: Other information
Other information : Items where changes have been made to the previous version are highlighted in the body of this document by two vertical lines.

Full text of H-Statements
H302 : Harmful if swallowed.
H319 : Causes serious eye irritation.
H361d : Suspected of damaging the unborn child.
H373 : May cause damage to organs through prolonged or repeated exposure.

Full text of other abbreviations
Acute Tox. : Acute toxicity
Eye Irrit. : Eye irritation
Repr. : Reproductive toxicity
STOT RE : Specific target organ toxicity - repeated exposure

ADN - European Agreement concerning the International Carriage of Dangerous Goods by Inland Waterways; ADR - European Agreement concerning the International Carriage of Dangerous Goods by Road; AICS - Australian Inventory of Chemical Substances; ASTM - American Society for the Testing of Materials; bw - Body weight; CLP - Classification Labelling Packaging Regulation; Regulation (EC) No 1272/2008; CMR - Carcinogen, Mutagen or Reproductive Toxicant; DIN - Standard of the German Institute for Standardisation; DSL - Domestic Substances List (Canada); ECHA - European Chemicals Agency; EC-Number - European Community number; ECx - Concentration associated with x% response; ELx - Loading rate associated with x% response; EmS - Emergency Schedule; ENCS - Existing and New Chemical Substances (Japan); ErCx - Concentration associated with x% growth rate response; GHS - Globally Harmonized System; GLP - Good Laboratory Practice; IARC - International Agency for Research on Cancer; IATA - In-
Moxifloxacin Solid Formulation

Version 2.2  Revision Date: 09/13/2019  SDS Number: 1732314-00006  Date of last issue: 24.04.2019
Date of first issue: 05.06.2017

Further information

Classification of the mixture:

| Acute Tox. 4 | H302 | Calculation method |
| Eye Irrit. 2 | H319 | Calculation method |
| Repr. 2 | H361d | Calculation method |
| STOT RE 2 | H373 | Calculation method |

The information provided in this Safety Data Sheet is correct to the best of our knowledge, information and belief at the date of its publication. The information is designed only as a guidance for safe handling, use, processing, storage, transportation, disposal and release and shall not be considered a warranty or quality specification of any type. The information provided relates only to the specific material identified at the top of this SDS and may not be valid when the SDS material is used in combination with any other materials or in any process, unless specified in the text. Material users should review the information and recommendations in the specific context of their intended manner of handling, use, processing and storage, including an assessment of the appropriateness of the SDS material in the user’s end product, if applicable.

NO / EN